Brief: Exicure Evaluating Impact Of COVID-19 On 2020 Forecast

Exicure

30/03/2020 22:10

March 30 (Reuters) - Exicure Inc  XCUR.O :
    * EXICURE PROVIDES BUSINESS UPDATE AMID COVID-19 PANDEMIC
    * PHASE 2 STAGE OF ITS PHASE 1B/2 CLINICAL TRIAL OF AST-008
IS
STILL EXPECTED TO BEGIN IN 2ND QUARTER
    * CURRENTLY EVALUATING IMPACT OF COVID-19 ON ITS 2020
FINANCIAL
GUIDANCE
    * CONTINUES TO PURSUE ITS PRE-CLINICAL DEVELOPMENT PROGRAMS
AND
CLINICAL PROGRAMS
    * AFFIRMS GUIDANCE THAT IND-ENABLING STUDIES FOR XCUR-FXN
ARE
EXPECTED IN LATE 2020
    * DOES NOT ANTICIPATE A CHANGE TO ITS PRIOR GUIDANCE AND
CONTINUES
TO BELIEVES ITS CURRENT CASH WILL FINANCE OPERATIONS INTO EARLY
2022
    * PRELIMINARY UNAUDITED CASH, CASH EQUIVALENTS AND
SHORT-TERM
INVESTMENTS AS OF FEBRUARY 29, 2020 WAS APPROXIMATELY $107.7
MILLION

Source text for Eikon:  ID:nBw1Dtt6za 
Further company coverage:  XCUR.O 

 ((Reuters.Briefs@thomsonreuters.com;))